Retatrutide Research

What Is Retatrutide? LY3437943, and What a Triple Agonist Does

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library1 min readLast reviewed 2026-08-294 cited sources

The short answer

Retatrutide (LY3437943) is an investigational triple-receptor agonist peptide developed by Eli Lilly. It binds and activates the GIP, GLP-1, and glucagon receptors simultaneously, making it the first triple-agonist incretin currently progressing through the Phase 3 TRIUMPH clinical trial programme.

Key facts

Chemical name
LY3437943 (Retatrutide)
Class
Triple receptor agonist (GIP/GLP-1/Glucagon)
Molecular weight
~4,731 Da
Developer
Eli Lilly and Company
Status
Investigational, pivotal Phase 3 reported
Approval
Not approved by FDA, EMA, or MHRA
TRIUMPH-1
28.3% mean reduction at 80 wks (May 2026)

What is retatrutide chemically?

Retatrutide is a 39-amino-acid synthetic peptide analogue derived from the GIP scaffold, engineered with fatty-acid conjugation to extend its plasma half-life. It is a single-molecule triple agonist: one peptide chain that binds three distinct incretin family receptors at physiologically relevant concentrations.

Who developed retatrutide?

Retatrutide is being developed by Eli Lilly and Company under the internal code LY3437943. The programme sits alongside Lilly's earlier incretin work on dulaglutide (Trulicity) and tirzepatide (Mounjaro / Zepbound), and represents the next generation beyond dual GIP/GLP-1 agonism.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What is its regulatory status?

Retatrutide is an investigational compound. It has not received marketing authorisation from the FDA, EMA or MHRA and is available only within clinical-trial and research settings. The pivotal Phase 3 trials have now reported (TRIUMPH-1 in May 2026, TRIUMPH-2 and -3 in July 2026), and Eli Lilly has signalled an intended FDA filing in the first quarter of 2027.

Why is it studied?

Phase 2 data in the New England Journal of Medicine (Jastreboff et al., 2023) reported the largest weight reductions then observed for any single-molecule incretin agonist. The Phase 3 programme has since reinforced that position: TRIUMPH-1 reported mean reduction of 28.3% at 80 weeks on its highest dose arm. This has made retatrutide one of the most widely referenced compounds in current metabolic pharmacology literature.

Frequently asked questions

Is retatrutide the same as tirzepatide?

No. Tirzepatide is a dual GIP/GLP-1 agonist; retatrutide adds glucagon-receptor activity, making it a triple agonist.

Is retatrutide approved anywhere?

No. Retatrutide has not been approved by any regulator worldwide and remains investigational, despite the pivotal Phase 3 trials having reported positively during 2026.

What does LY3437943 mean?

It is Eli Lilly's internal development code for retatrutide, used in trial registrations and published research.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More Retatrutide Research articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.